SPRY2 Antibody

中文名稱：

SPRY2兔多克隆抗體
貨號：

CSB-PA022622LA01HU
規格：

￥440
圖片：
Western Blot
Positive WB detected in: NIH/3T3 whole cell lysate, Jurkat whole cell lysate, HEK293 whole cell lysate
All lanes: SPRY2 antibody at 2.7μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 40 kDa
Observed band size: 40 kDa

Immunohistochemistry of paraffin-embedded human brain tissue using CSB-PA022622LA01HU at dilution of 1:100

Immunofluorescent analysis of HepG2 cells using CSB-PA022622LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) SPRY2 Polyclonal antibody
Uniprot No.：

O43597
基因名：

SPRY2
宿主：

Rabbit
反應種屬：

Human, Mouse
免疫原：

Recombinant Human SPRY2 protein (2-97AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，SPRY2 Antibody (CSB-PA022622LA01HU)，的標記方式是Non-conjugated。對于SPRY2 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA022622LB01HU	SPRY2 Antibody, HRP conjugated	ELISA
FITC	CSB-PA022622LC01HU	SPRY2 Antibody, FITC conjugated
Biotin	CSB-PA022622LD01HU	SPRY2 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2. Thereby acts as an antagonist of FGF-induced retinal lens fiber differentiation, may inhibit limb bud outgrowth and may negatively modulate respiratory organogenesis. Inhibits TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells. Inhibits CBL/C-CBL-mediated EGFR ubiquitination.
基因功能參考文獻：
1. Overexpression of miR-592 promotes GC proliferation, migration, and invasion and induces the EMT via the PI3K/AKT and MAPK/ERK signaling pathways by inhibiting Spry2, suggesting a potential therapeutic target for Gastric cancer. PMID: 29949784
2. nuclear Spry2 acts as a molecular link which co-ordinates airway and vascular growth of the cardiopulmonary system. PMID: 29409968
3. activation of ERK1/2 signaling was required for hCG-induced up-regulation of SPRY2 expression. Further, SPRY2 knockdown attenuated the AREG-induced COX-2 expression and PGE2 production by inhibiting AREG-activated ERK1/2 signaling. PMID: 27539669
4. Result demonstrated that SPRY2 low-expression was significantly associated with unfavorable prognosis of gastric adenocarcinoma and that SPRY2 could inhibit FGFR2-induced ERK phosphorylation and suppress FGFR2-elicited gastric cancer cell proliferation and invasion. PMID: 28002800
5. Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells. PMID: 27835572
6. Sprouty2 (Spry2), a negative regulator of the extracellular signal regulated kinase/mitogen-activated protein kinase (Erk/MAPK) signalling pathway, was a downstream target of miR-122-5p possibly involved in regulating the keratinocyte proliferation. PMID: 27943426
7. results shows the involvement of Spry2 in regulation of FosB and Runx2 genes, MAPK signaling and proliferation of mesenchymal stem cells. PMID: 28387432
8. MYB acts on MAPK signaling by directly regulating transcription of the gene encoding the negative modulator SPRY2. PMID: 27748374
9. ZEB1 upregulation by SPRY2 results from the combined induction of ETS1 transcription factor and the repression of microRNAs (miR-200 family, miR-150) that target ZEB1 RNA. Moreover, SPRY2 increased AKT activation by epidermal growth factor, whereas AKT and also Src inhibition reduced the induction of ZEB1. PMID: 26455323
10. upregulated in human CRC. Suppression of SPRY2 repressed AKT2 and EMT-inducing transcription factors and significantly increased E-cadherin expression. Concurrent downregulation of SPRY1 and SPRY2 also increased E-cadherin and suppressed mesenchymal markers in colon cancer cells. PMID: 26434583
11. In cells harbouring a K-Ras mutation the serine conversion weakens the reduction of migration velocity indicating that dependent on the status of K-Ras the serine influences Sprouty2 functions differently. PMID: 26727965
12. Increased nuclear localization of p21(WAF1/CIP1) in SPRY2 downregulated colon cancer cells may explain the inhibition of cell proliferation in colon cancer cells. PMID: 26293890
13. Data suggest a common mechanism by which DNA methyltransferase1 (DNMT1) and hypoxia inducible factors HIF1alpha/HIF2alpha regulate Sprouty2 (Spry2) transcription. PMID: 28196140
14. We showed that Spry2 is a novel unfolded protein response target and its upregulation is dependent on PERK. PMID: 28246293
15. has an inhibitory role in TGFbeta signaling pathway in lens epithelial cells PMID: 27415760
16. these results establish SPRY2 as a critical negative regulator of BCR-mediated MAPK-Erk signaling in chronic lymphocytic leukemia , thereby providing one of the molecular mechanisms to explain the clinical heterogeneity of chronic lymphocytic leukemia. PMID: 26809508
17. spry2 can inhibit MM cell growth and survival with a concomitant reduction in phosphorylation of extracellular signal-regulated kinases 1 and 2 in vitro and in vivo. PMID: 27016275
18. data suggest that Spry2 acts as a scaffold to bring more pVHL/associated E3 ligase in proximity of HIF1alpha and increase its ubiquitylation and degradation. This represents a novel action for Spry2 in modulating biological processes regulated by HIFalpha subunits. PMID: 27281823
19. MiR-122 could act as a tumor promoter and potentially target Sprouty2. MiR-122 promotes renal cell carcinoma cell proliferation, migration, and invasion. PMID: 28231730
20. miR27b promotes the migration and invasion of gastric cancer cells via inhibition of SPRY2mediated ERK signaling. PMID: 26781754
21. Arg119Trp variant in the SPRY2 gene was identified as the probable IgA nephropathy-causing mutation. This variant is responsible for inhibition of the MAPK/ERK1/2 pathway. PMID: 25782674
22. SPRY2, counter to its roles in other cancer settings, promotes glioma cell and tumor growth and cellular resistance to targeted inhibitors of oncogenic RTKs PMID: 25934697
23. Data show that proto-oncogene protein B-raf (BRAF) inhibition induces c-Jun N-terminal kinase (c-JUN) expression and c-JUN abundance and activation by down-regulating SPRY2/4 protein expression. PMID: 26286024
24. The purpose of this study was to determine whether SPRY2 might have antiinflammatory effects on rheumatoid arthritis fibroblast-like synoviocytes. PMID: 26265114
25. miR21 may represent a negative regulator involved in the downregulation of SPRY2 in MM. PMID: 25633921
26. No association between SPRY2, single-nucleotide polymorphisms, and nonsyndromic cleft lip with or without cleft palate risk were observed in this cohort of patients. PMID: 25339627
27. A decrease in SPRY2 and RECK expression by nickel-induced miR-21 may promote invasiveness in lung cancer cells. PMID: 26026961
28. Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer. PMID: 25630587
29. Results suggest a link between placental SPRY2 mRNA levels and placental growth, which may be modulated by maternal metabolic status and placental inflammation. PMID: 24969401
30. This study reveals the loss of SPRY2 in HGSC and indicates an important tumor-suppressive role for SPRY2 in mediating the stimulatory effect of EGF on human EOC progression. PMID: 25533808
31. CK1 activity and binding are necessary for SPRY2 inhibition of FGF-stimulated neurite outgrowth in PC12 cells PMID: 24469046
32. Data indicate that the proliferation and survival rates of HEK293T cells transfected with pDC315/hSPRY2 were significantly higher than those transfected with pDC315/EGFP (green fluorescent proteins). PMID: 24796743
33. Mechanistic model of EGFR endocytosis to determine the relative contributions of three parallel pathways of MIG6, ubiquitin ligase CBL and Sprouty2. PMID: 24445374
34. The ERK-MAPK signaling pathway is regulated by Sprouty2 expression via a miR-21-mediated mechanism during mesenchymal stem cell differentiation. PMID: 23239100
35. SPRY2 and MIG6 are important regulators of wild-type and mutant EGFR trafficking and points to an EGFR expression-independent function of SPRY2 in the regulation of ERK activity that may impact cellular sensitivity to EGFR inhibitors PMID: 23868981
36. involvement of PAX9, EDA, SPRY2, SPRY4, and WNT10A as risk factors for MLIA. uncovered 3 strong synergistic interactions between MLIA liability and MSX1-TGFA, AXIN2-TGFA, and SPRY2-SPRY4 gene pairs. 1st evidence of sprouty genes in MLIA susceptibility. PMID: 24554542
37. we reveal that SPRY2 expression is regulated by FOXO3a and beta-catenin nuclear activity in colon cancer PMID: 23624922
38. Increased SPRY2 expression during chronic viral infection reduces T cell polyfunctionality. PMID: 24292711
39. hypothesize that the level of SPRY2 expression contributes to MAPK/ERK pathway output and accounts for BRAF V600E+ and clinical heterogeneity in papillary thyroid cancer PMID: 24094449
40. Sprouty2 (but not Sprouty4) has a role in inhibition of cell proliferation and migration of osteosarcoma cells PMID: 23831057
41. SPRY2 is an important regulator of branching morphogenesis and epithelial to mesenchymal transition in the mammary gland. PMID: 23573284
42. Our results have raised the possibility that Spry2 might play a role in the pathogenesis and progression of renal cell carcinoma. PMID: 23688375
43. Data suggest epidermal growth factor induced the expression of c-MYC, which promoted the expression of mature miR-23a, miR-24-2, and miR-27a and subsequently decreased expression of Sprouty2 (SPRY2). PMID: 23649631
44. miR-27a regulates MET, EGFR, and Sprouty2 in lung cancer. PMID: 23650389
45. SPRY2, PTEN, and PP2A status is an important determinant of prostate cancer progression. PMID: 23434594
46. In conclusion, SPRY2 is an important tumour suppressor in prostate cancer since its loss drives the PI3K/AKT pathway via functional interaction with the ErbB system. PMID: 22649008
47. G Protein-regulated inducer of neurite outgrowth (GRIN) modulates Sprouty protein repression of mitogen-activated protein kinase (MAPK) activation by growth factor stimulation PMID: 22383529
48. ITSN1 binds Pro-rich regions in both Cbl and Spry2, and interaction of ITSN1 with Spry2 disrupts Spry2-Cbl interaction, resulting in enhanced ubiquitylation of the EGFR. PMID: 22158968
49. A significant association of rs10906115 in CDC123/CAMK1D and rs1359790 near SPRY2 was identified with type 2 diabetes in a Japanese population. PMID: 21909839
50. analysis of regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins PMID: 22006925
顯示更多

收起更多
相關疾病：

IgA nephropathy 3 (IGAN3)
亞細胞定位：

Cytoplasm, cytoskeleton. Cell projection, ruffle membrane.
蛋白家族：

Sprouty family
數據庫鏈接：

HGNC: 11270

OMIM: 602466

KEGG: hsa:10253

STRING: 9606.ENSP00000366306

UniGene: Hs.18676

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human